Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00420342
Status:
COMPLETED
Last Update Posted:
2015-06-02
First Post:
2007-01-09
Brief Title:
Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Double Blind Randomized Active-control Study to Evaluate Effects of DrospirenoneEstradiol Angeliq and Medroxyprogesterone AcetateConjugated Equine Estrogen Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq and Prempro on blood pressure in post-menopausal women with prehypertension
Detailed Description:
This study has previously been posted by Berlex Inc Berlex Inc has been renamed to Bayer HealthCare Pharmaceuticals IncBayer HealthCare Pharmaceuticals Inc is the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 310522 | OTHER | Company internal | None |